全文获取类型
收费全文 | 1245篇 |
免费 | 78篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 41篇 |
妇产科学 | 10篇 |
基础医学 | 120篇 |
口腔科学 | 14篇 |
临床医学 | 110篇 |
内科学 | 333篇 |
皮肤病学 | 2篇 |
神经病学 | 82篇 |
特种医学 | 318篇 |
外科学 | 66篇 |
综合类 | 22篇 |
一般理论 | 4篇 |
预防医学 | 126篇 |
眼科学 | 7篇 |
药学 | 62篇 |
中国医学 | 1篇 |
肿瘤学 | 26篇 |
出版年
2021年 | 15篇 |
2018年 | 21篇 |
2017年 | 12篇 |
2015年 | 18篇 |
2014年 | 19篇 |
2013年 | 14篇 |
2012年 | 30篇 |
2011年 | 29篇 |
2010年 | 19篇 |
2009年 | 30篇 |
2008年 | 24篇 |
2007年 | 53篇 |
2006年 | 32篇 |
2005年 | 29篇 |
2004年 | 22篇 |
2003年 | 16篇 |
2002年 | 23篇 |
2001年 | 12篇 |
2000年 | 16篇 |
1999年 | 26篇 |
1998年 | 49篇 |
1997年 | 40篇 |
1996年 | 63篇 |
1995年 | 47篇 |
1994年 | 41篇 |
1993年 | 42篇 |
1992年 | 21篇 |
1991年 | 23篇 |
1990年 | 24篇 |
1989年 | 37篇 |
1988年 | 45篇 |
1987年 | 37篇 |
1986年 | 33篇 |
1985年 | 46篇 |
1984年 | 23篇 |
1983年 | 26篇 |
1982年 | 27篇 |
1981年 | 27篇 |
1980年 | 16篇 |
1979年 | 9篇 |
1978年 | 17篇 |
1977年 | 35篇 |
1976年 | 20篇 |
1975年 | 23篇 |
1973年 | 9篇 |
1972年 | 11篇 |
1969年 | 12篇 |
1968年 | 11篇 |
1967年 | 7篇 |
1966年 | 7篇 |
排序方式: 共有1345条查询结果,搜索用时 15 毫秒
31.
Splenic lymphangiomatosis in children 总被引:14,自引:0,他引:14
32.
Red blood cell (RBC) protein 4.2 deficiency is often associated with a moderate nonimmune hemolytic anemia, splenomegaly, and osmotically fragile RBCs resembling, but not identical to, hereditary spherocytosis (HS). In the Japanese type of protein 4.2 deficiency (protein 4.2Nippon), the anemia is associated with a point mutation in the protein 4.2 cDNA. In this report, we describe a patient with moderate and apparently episodic nonimmune hemolytic anemia with splenomegaly, spherocytosis, osmotically fragile RBCs, reduced whole cell deformability, and abnormally dense cells. Sodium dodecyl sulfate- polyacrylamide gel electrophoresis analysis of the proposita's RBC membrane proteins showed an 88% deficiency of protein 4.2 and a 30% deficiency of glyceraldehyde-3-phosphate dehydrogenase (band 6). Structural and molecular analyses of the proposita's protein 4.2 were normal. In contrast, limited tryptic digestion of the proposita's band 3 showed a homozygous abnormality in the cytoplasmic domain. Analysis of the pedigree disclosed six members who were heterozygotes for the band 3 structural abnormality and one member who was a normal homozygote. Direct sequence analysis of the abnormal band 3 tryptic peptide suggested that the structural abnormality resided at or near residue 40. Sequence analysis of the proposita's band 3 cDNA showed a 232G-->A mutation resulting in a 40glutamic acid-->lysine substitution (band 3Montefiore). Allele-specific oligonucleotide hybridization was used to probe for the mutation in the pedigree, showing that the proposita was homozygous, and the pedigree members who were heterozygous for the band 3 structural abnormality were also heterozygous for the band 3Montefiore mutation. The band 3Montefiore mutation was absent in 26 chromosomes from race-matched controls and in one pedigree member who did not express the band 3 structural abnormality. In coincidence with splenectomy, the proposita's anemia was largely corrected along with the disappearance of most spherocytes and considerable improvements of RBC osmotic fragility, whole cell deformability, and cell density. We conclude that this hereditary hemolytic anemia is associated with the homozygous state for band 3Montefiore (40glutamic acid-->lysine) and a decreased RBC membrane content of protein 4.2. We speculate that band 3 structural abnormalities can result in defective interactions with protein 4.2 and band 6, and in particular, that the region of band 3 containing 40glutamic acid is involved directly or indirectly in interactions with these proteins. 相似文献
33.
34.
35.
36.
37.
Boska MD Mosley RL Nawab M Nelson JA Zelivyanskaya M Poluektova L Uberti M Dou H Lewis TB Gendelman HE 《Current HIV research》2004,2(1):61-78
Persons with advanced human immunodeficiency virus type one (HIV-1) infection seek medical advice for a wide range of neurological disorders including, but not limited to, peripheral neuropathy, toxoplasmosis, cryptococcal meningitis, cytomegalovirus retinitis progressive multifocal leukoencephalopathy, lymphoma and dementia. The diagnosis of HIV-1-associated dementia (HAD) induced as a direct consequence of HIV infection of the brain comes commonly by exclusion. Diagnostic decisions can often be clouded by concomitant depression, motor impairments, and lethargy that follow debilitating immune suppression and weight loss. Indeed, cognitive, motor and behavior abnormalities underlie a variety of neurological dysfunctions associated with advanced HIV-1 infection. Thus, even combinations of clinical, laboratory and neuroimaging tests [for example, magnetic resonance imaging (MRI), computed tomography (CT), single photon emission computed tomography (SPECT) and positron emission tomography (PET)] often fail to provide conclusive diagnostic information. Nonetheless, the recent development of quantitative MR spectroscopic imaging has improved diagnostic possibilities for HAD. We are pleased to discuss these developments as well as taking a forward look into what will soon be made available to improve neuroimaging diagnostic precision. New MR and SPECT testing are being developed in our laboratories and elsewhere both for animal model systems and in humans with HIV-1 disease. Such tests can facilitate dynamic measures of HIV-1 neuropathogenesis providing information for disease events that even 2 years ago were unattainable. 相似文献
38.
Hanchen Xu Kevin Van der Jeught Zhuolong Zhou Lu Zhang Tao Yu Yifan Sun Yujing Li Changlin Wan Ka Man So Degang Liu Michael Frieden Yuanzhang Fang Amber L. Mosley Xiaoming He Xinna Zhang George E. Sandusky Yunlong Liu Samy O. Meroueh Chi Zhang Aruna B. Wijeratne Cheng Huang Guang Ji Xiongbin Lu 《The Journal of clinical investigation》2021,131(10)
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy. 相似文献
39.
Woods CW McRill C Plikaytis BD Rosenstein NE Mosley D Boyd D England B Perkins BA Ampel NM Hajjeh RA 《The Journal of infectious diseases》2000,181(4):1428-1434
From 1 January 1995 through 31 June 1997, 153 cases of coccidioidomycosis in human immunodeficiency virus (HIV)-infected persons were identified in Arizona (incidence, 41/1000 persons living with AIDS). A case-control study was conducted to evaluate risk factors for coccidioidomycosis in HIV-infected persons. A case was defined as laboratory-confirmed, incident coccidioidomycosis in a person infected with HIV for > or =3 months, and each case patient had 3 control patients matched by county, age group, sex, HIV/AIDS status, and CD4 lymphocyte count. Multivariable analysis identified black race and a history of oropharyngeal or esophageal candidiasis to be associated with increased risk of coccidioidomycosis; protease inhibitor therapy was associated with a reduced risk. In persons with previous history of oropharyngeal or esophageal candidiasis, having received an azole drug was associated with a reduced risk (odds ratio, 0.4; 95% confidence interval, 0.2-0.9; P=.04). Physicians may need to consider azole chemoprophylaxis for HIV-infected persons who live in areas of endemicity, have CD4 cell counts <200/microL, are black, or have a history of thrush. 相似文献
40.
Willingham SB Volkmer JP Gentles AJ Sahoo D Dalerba P Mitra SS Wang J Contreras-Trujillo H Martin R Cohen JD Lovelace P Scheeren FA Chao MP Weiskopf K Tang C Volkmer AK Naik TJ Storm TA Mosley AR Edris B Schmid SM Sun CK Chua MS Murillo O Rajendran P Cha AC Chin RK Kim D Adorno M Raveh T Tseng D Jaiswal S Enger PØ Steinberg GK Li G So SK Majeti R Harsh GR van de Rijn M Teng NN Sunwoo JB Alizadeh AA Clarke MF Weissman IL 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(17):6662-6667
CD47, a "don't eat me" signal for phagocytic cells, is expressed on the surface of all human solid tumor cells. Analysis of patient tumor and matched adjacent normal (nontumor) tissue revealed that CD47 is overexpressed on cancer cells. CD47 mRNA expression levels correlated with a decreased probability of survival for multiple types of cancer. CD47 is a ligand for SIRPα, a protein expressed on macrophages and dendritic cells. In vitro, blockade of CD47 signaling using targeted monoclonal antibodies enabled macrophage phagocytosis of tumor cells that were otherwise protected. Administration of anti-CD47 antibodies inhibited tumor growth in orthotopic immunodeficient mouse xenotransplantation models established with patient tumor cells and increased the survival of the mice over time. Anti-CD47 antibody therapy initiated on larger tumors inhibited tumor growth and prevented or treated metastasis, but initiation of the therapy on smaller tumors was potentially curative. The safety and efficacy of targeting CD47 was further tested and validated in immune competent hosts using an orthotopic mouse breast cancer model. These results suggest all human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination. These data, taken together with similar findings with other human neoplasms, show that CD47 is a commonly expressed molecule on all cancers, its function to block phagocytosis is known, and blockade of its function leads to tumor cell phagocytosis and elimination. CD47 is therefore a validated target for cancer therapies. 相似文献